What's a fair offer from Pfizer?, page-26

We are pissed because we know the market for both acute respiratory disease and chronic respiratory management for Asthma and COPD given this will be for all age demographic (except COPD will only be adult) and this is even before COVID-19 screening. IMO, Pfizer will need to increase this to 25-30c for even a chance the top 20 holders will budge so will definitely be interesting what happen.

Big pharmacy like Pfizer can pay a "premium" to the current pps given the MC was so bloody low but the LT know the potential of RAP's products and the market want to see revenue with RAP finally starting to show this for ResAppDx-EU last quarter, hence the pps rose on those financial numbers even with a miniscule fraction of the market captured.